Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$5.22 USD
+0.06 (1.16%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $5.22 0.00 (0.00%) 7:52 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALDX 5.22 +0.06(1.16%)
Will ALDX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Other News for ALDX
Aldeyra Therapeutics to Participate in the H.C. ...
ALDX Gains Orphan Status in Europe for Vision Loss Treatment | ALDX Stock News
Aldeyra receives orphan designation for ADX-2191 from EMA
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ...
Commit To Buy Aldeyra Therapeutics At $2.50, Earn 28.4% Annualized Using Options